---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-299492"
form_type: "8-K"
ticker: null
cik: "0001593034"
company_name: "Endo International plc"
filed_at: "2022-12-06T23:59:59+00:00"
generated_at: "2026-06-21T08:53:32.345590+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Endo ceases QWO production & sales due to bruising concerns; expects $235-250M Q4 restructuring charges

## Summary
- Ceasing Endo Aesthetics' QWO (cellulite treatment) due to market concerns about bruising and skin discoloration.
- Annualized pre-tax cash savings of $50-60M; workforce reduction of ~90 positions.
- Q4 2022 pre-tax restructuring charges of $235-250M, mainly non-cash asset impairment of $220-230M.
- Seeking bankruptcy court approval for the decision; QWO remains FDA-approved but not commercially viable.
- APHRODITE study showed modest bruising reduction but not enough to alleviate market concerns.

## SEC filing metadata
- accession: 0001193125-22-299492
- form_type: 8-K
- cik: 0001593034
- company_name: Endo International plc
- filed_at: 2022-12-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 2.06, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593034/000119312522299492/0001193125-22-299492-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593034/000119312522299492/d410746d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-299492
- JSON: https://secwatch.observer/filing/0001193125-22-299492.json
- Plain text: https://secwatch.observer/filing/0001193125-22-299492.txt

## Key facts
- Restructurings & Charges
  Endo International plc announced a restructuring with charges of approximately $235 million to $250 million affecting Endo Aesthetics’ QWO product line (approximately 90 full-time positions).
  - Type: restructuring
  - Charge: approximately $235 million to $250 million
  - Affected area: Endo Aesthetics’ QWO product line
  - Headcount: approximately 90 full-time positions
  source text: On December 6, 2022, Endo International plc (together with its direct and indirect subsidiaries, “ Endo ” or the “ Company ”) announced that it will cease the production and sale of Endo Aesthetics’ QWO ® (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration. This decision is expected to result in annualized pre-tax cash savings of approximately $50 million to $60 million and a reduction to Endo’s global workforce of approximately 90 full-time positions. In connection with ceasing production and sales of QWO ® , Endo expects to incur total pre-tax restructuring charges of approximately $235 million to $250 million in the fourth quarter 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1593034/000119312522299492/0001193125-22-299492-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.